SG11202101757QA - Novel cancer immunotherapy antibody compositions - Google Patents
Novel cancer immunotherapy antibody compositionsInfo
- Publication number
- SG11202101757QA SG11202101757QA SG11202101757QA SG11202101757QA SG11202101757QA SG 11202101757Q A SG11202101757Q A SG 11202101757QA SG 11202101757Q A SG11202101757Q A SG 11202101757QA SG 11202101757Q A SG11202101757Q A SG 11202101757QA SG 11202101757Q A SG11202101757Q A SG 11202101757QA
- Authority
- SG
- Singapore
- Prior art keywords
- cancer immunotherapy
- antibody compositions
- novel cancer
- immunotherapy antibody
- novel
- Prior art date
Links
- 238000002619 cancer immunotherapy Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862720015P | 2018-08-20 | 2018-08-20 | |
| PCT/CN2019/101659 WO2020038379A1 (en) | 2018-08-20 | 2019-08-20 | Novel cancer immunotherapy antibody compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202101757QA true SG11202101757QA (en) | 2021-03-30 |
Family
ID=69591356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202101757QA SG11202101757QA (en) | 2018-08-20 | 2019-08-20 | Novel cancer immunotherapy antibody compositions |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210332138A1 (en) |
| EP (1) | EP3841126A4 (en) |
| JP (1) | JP7488534B2 (en) |
| KR (1) | KR20210046725A (en) |
| CN (3) | CN112839963B (en) |
| AU (1) | AU2019324388A1 (en) |
| BR (1) | BR112021003182A2 (en) |
| CA (1) | CA3110138A1 (en) |
| MX (1) | MX2021002077A (en) |
| SG (1) | SG11202101757QA (en) |
| TW (1) | TW202016150A (en) |
| WO (1) | WO2020038379A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023187460A1 (en) * | 2022-04-01 | 2023-10-05 | Mabtree Biologics Ag | Human antibody or antigen binding fragment thereof specific against pd-l1 to enhance t-cell function |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101888321B1 (en) * | 2005-07-01 | 2018-08-13 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | Human monoclonal antibodies to programmed death ligand 1(pd-l1) |
| EP1945257A4 (en) * | 2005-08-08 | 2009-05-06 | Onconon Llc | Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility |
| WO2010036959A2 (en) * | 2008-09-26 | 2010-04-01 | Dana-Farber Cancer Institute | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor |
| KR20210060670A (en) * | 2008-12-09 | 2021-05-26 | 제넨테크, 인크. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| WO2011066389A1 (en) * | 2009-11-24 | 2011-06-03 | Medimmmune, Limited | Targeted binding agents against b7-h1 |
| CA2856895C (en) * | 2011-11-28 | 2021-10-26 | Merck Patent Gmbh | Anti-pd-l1 antibodies and uses thereof |
| AU2013267161A1 (en) * | 2012-05-31 | 2014-11-20 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-L1 |
| AR093984A1 (en) * | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | ANTIBODIES THAT JOIN LEGEND 1 OF SCHEDULED DEATH (PD-L1) HUMAN |
| CN105777906B (en) * | 2014-12-19 | 2019-04-23 | 苏州丁孚靶点生物技术有限公司 | Anti- PD-L1 human antibody and its application |
| MX2017011600A (en) * | 2015-03-10 | 2018-06-13 | Sorrento Therapeutics Inc | Antibody therapeutics that bind psma. |
| TWI733687B (en) * | 2015-07-22 | 2021-07-21 | 美商索倫多醫療公司 | Antibody therapeutics that bind lag3 |
| WO2017020291A1 (en) * | 2015-08-06 | 2017-02-09 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| CN106432501B (en) * | 2015-08-06 | 2021-07-30 | 基石药业 | Novel anti-PD-L1 antibodies |
| CN116333124A (en) * | 2016-01-29 | 2023-06-27 | 索伦托药业有限公司 | Antigen binding proteins that bind to PD-L1 |
| CN113773387B (en) * | 2016-06-13 | 2024-06-21 | 天境生物科技(上海)有限公司 | PD-L1 antibodies and uses thereof |
| CN106496327B (en) * | 2016-11-18 | 2019-01-15 | 昆山百尔泰生物科技有限公司 | Human antibody or antibody fragment and purposes, nucleotide sequence and carrier for PD-L1 extracellular fragment |
| CN108239149B (en) * | 2016-12-25 | 2021-03-05 | 南京传奇生物科技有限公司 | High-affinity, high-specificity and higher-functionality anti-human PD-L1 antibody with multiple antigen recognition epitopes |
| CN107973854B (en) * | 2017-12-11 | 2021-05-04 | 苏州银河生物医药有限公司 | PDL1 monoclonal antibody and application thereof |
| SG11202104297XA (en) * | 2018-10-29 | 2021-05-28 | 1Globe Biomedical Co Ltd | Novel rationally designed protein compositions |
-
2019
- 2019-08-20 CA CA3110138A patent/CA3110138A1/en active Pending
- 2019-08-20 JP JP2021509199A patent/JP7488534B2/en active Active
- 2019-08-20 CN CN201980054723.0A patent/CN112839963B/en active Active
- 2019-08-20 CN CN202211332831.XA patent/CN116063519A/en active Pending
- 2019-08-20 BR BR112021003182-0A patent/BR112021003182A2/en unknown
- 2019-08-20 US US17/270,034 patent/US20210332138A1/en active Pending
- 2019-08-20 AU AU2019324388A patent/AU2019324388A1/en active Pending
- 2019-08-20 CN CN202310026623.5A patent/CN116410320A/en active Pending
- 2019-08-20 TW TW108129705A patent/TW202016150A/en unknown
- 2019-08-20 WO PCT/CN2019/101659 patent/WO2020038379A1/en active Application Filing
- 2019-08-20 SG SG11202101757QA patent/SG11202101757QA/en unknown
- 2019-08-20 EP EP19853152.7A patent/EP3841126A4/en active Pending
- 2019-08-20 KR KR1020217008130A patent/KR20210046725A/en unknown
- 2019-08-20 MX MX2021002077A patent/MX2021002077A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20210332138A1 (en) | 2021-10-28 |
| AU2019324388A1 (en) | 2021-03-18 |
| TW202016150A (en) | 2020-05-01 |
| BR112021003182A2 (en) | 2021-05-11 |
| CN116063519A (en) | 2023-05-05 |
| JP2021534750A (en) | 2021-12-16 |
| EP3841126A1 (en) | 2021-06-30 |
| JP7488534B2 (en) | 2024-05-22 |
| CN112839963A (en) | 2021-05-25 |
| CN116410320A (en) | 2023-07-11 |
| KR20210046725A (en) | 2021-04-28 |
| CA3110138A1 (en) | 2020-02-27 |
| EP3841126A4 (en) | 2022-08-10 |
| MX2021002077A (en) | 2021-05-27 |
| CN112839963B (en) | 2023-02-10 |
| WO2020038379A1 (en) | 2020-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL288754A (en) | Compositions and methods for cancer immunotherapy | |
| SG11202106214YA (en) | Novel anti-ccr8 antibody | |
| IL282080A (en) | Combinatorial cancer immunotherapy | |
| IL282225A (en) | Compositions and methods for immunotherapy | |
| SG11202108141VA (en) | Novel cd40-binding antibodies | |
| IL278010A (en) | Galectin-10 antibodies | |
| IL283625A (en) | Diagnostic methods and compositions for cancer immunotherapy | |
| IL292727A (en) | Multispecific antibody | |
| EP3597766A4 (en) | Novel biomarker for cancer immunotherapy | |
| IL277030A (en) | Antibodies | |
| EP3500262A4 (en) | Compositions and methods for cancer immunotherapy | |
| GB202110263D0 (en) | Anti-btla antibodies | |
| EP3892333A4 (en) | Tumor combined immunotherapy | |
| SG11202007735TA (en) | Anti-her2 antibodies | |
| IL283076A (en) | Methods and compositions for cancer immunotherapy | |
| IL280278A (en) | Fcrn antibody compositions | |
| IL283644A (en) | Compositions and methods for immunotherapy | |
| EP4025204A4 (en) | Cancer immunotherapy | |
| IL289006A (en) | Combination cancer immunotherapy | |
| GB201903229D0 (en) | Immunotherapy | |
| EP3752194A4 (en) | Compositions and methods for tumor immunotherapy | |
| GB201806084D0 (en) | Antibodies | |
| EP3858994A4 (en) | Antibody composition | |
| EP3768725A4 (en) | Novel anti-tim-3 antibodies | |
| SG11202101757QA (en) | Novel cancer immunotherapy antibody compositions |